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Background: Comorbidity indices summarize complex medical histories into concise ordinal 
scales, facilitating stratification and regression in epidemiologic analyses. Low subject prevalence 
in the highest strata of a comorbidity index often prompts combination of upper categories into 
a single stratum (‘collapsing’).
Objective: We use data from a breast cancer cohort to illustrate potential inferential errors 
resulting from collapsing a comorbidity index.
Methods: Starting from a full index (0, 1, 2, 3, and 4 comorbidities), we sequentially collapsed 
upper categories to yield three collapsed categorizations. The full and collapsed categorizations 
were applied to analyses of (1) the association between comorbidity and all-cause mortality, 
wherein comorbidity was the exposure; (2) the association between older age and all-cause 
mortality, wherein comorbidity was a candidate confounder or effect modifier.
Results: Collapsing the index attenuated the association between comorbidity and mortality (risk 
ratio, full versus dichotomized categorization: 4.6 vs 2.1), reduced the apparent magnitude of 
confounding by comorbidity of the age/mortality association (relative risk due to confounding, 
full versus dichotomized categorization: 1.14 vs 1.09), and obscured modification of the 
association between age and mortality on both the absolute and relative scales.
Conclusions: Collapsing categories of a comorbidity index can alter inferences concerning 
comorbidity as an exposure, confounder and effect modifier.
Keywords: epidemiology, breast neoplasms, comorbidity, confounding factors (epidemiologic), 
bias (epidemiologic), statistical models
Introduction
Proper accounting for comorbid diseases – medical conditions co-prevalent with 
a diagnosis of clinical or research interest1 – has been a long-standing emphasis in 
the practice of clinical epidemiology. To this end, comorbidity indices have been 
developed to summarize complex medical histories in consolidated ordinal scales, 
offering statistical efficiency and straightforward interpretation compared with the 
inclusion of individual comorbid diseases in statistical models or stratified analyses.2,3 
The simplest comorbidity index is the sum of diseases co-prevalent with the studied 
diagnosis. This approach can be augmented by incorporating disease severity through 
empirical weighting systems.2,4–6
Regardless of the chosen index, comorbidity may be treated as an exposure, 
candidate confounder, or effect modifier in epidemiologic analyses. The prevalence 
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of subjects in the highest categories of a comorbidity 
index is usually much lower than the prevalence in lower 
categories. The consequential data sparsity often motivates 
the combination of one or more upper categories into a 
single stratum. Lash recently explained the potentially 
hazardous consequences of collapsing upper categories 
of comorbidity indices for the sake of statistical efficiency 
or ease of interpretation.7 Examples of such collapsing 
are common in the literature, even in studies with rather 
large sample sizes where data sparsity was not likely the 
chief inducement for doing so. For instance, Elkin and 
colleagues used a modified Charlson Comorbidity Index2 
to represent comorbidity as a confounder in an analysis 
of chemotherapy exposure and survival among older 
women with hormone receptor-negative breast cancer.8 
The Charlson Comorbidity Index is an ordinal variable 
ranging in value from 0 to 3, yet the authors combined the 
two highest categories (scores of 2 and 3) into one stra-
tum with over 650 subjects. In a larger study of adjuvant 
chemotherapy in breast cancer, Giordano and colleagues 
also chose to collapse the two highest categories of the 
Charlson Comorbidity Index, yielding a collapsed stratum 
with over 3,800 subjects.9 There are also published stud-
ies in which a collapsed comorbidity index was a primary 
epidemiologic exposure.10–12
Herein we illustrate the potentially hazardous consequences 
of collapsing upper categories of a comorbidity index7 
using data from the Breast Cancer Treatment in Older 
Women (BOW) cohort study.13 We evaluate the association 
between a simple index of comorbidity and the risk of death 
from any cause, examine confounding by comorbidity of 
the association between older age and all-cause mortality, 
and assess modification of the age/mortality association 
by comorbidity. In all three scenarios we demonstrate the 
impact of collapsing upper categories of the comorbidity 
index on the inferences obtained under full categorization. 
We also illustrate a risk trend analysis using polynomial 
regression, a proposed alternative to categorical statistics 
for depicting dose-response relations between an exposure 
and an outcome.14 Finally, we discuss restricting analyses 
to comorbidity categories of sufficient size as a simple 
alternative to collapsing.
Methods
Study population
We conducted this study in the BOW cohort of older women 
diagnosed with early stage breast cancer who were recruited 
from integrated health systems participating in the HMO 
Cancer Research Network (CRN).15 The CRN consists of 
the research programs, enrollee populations, and databases of 
14 members of the HMO Research Network. The main goal 
of the CRN is to conduct collaborative research to determine 
the effectiveness of preventive, curative, and supportive inter-
ventions for major cancers that span the natural history of those 
cancers among diverse populations and health systems.
Data collection procedures for the BOW cohort are 
thoroughly described in an earlier publication.13 Briefly, 
women age 65 years with a histologically-confirmed first 
diagnosis of American Joint Commission on Cancer TNM 
stage16 I or II breast cancer between January 1, 1990 and 
December 31, 1994 who were enrolled in six geographically 
diverse health systems (Group Health Cooperative, Seattle, 
Washington; Kaiser Permanente Southern California; 
Lovelace/Sandia Health System, New Mexico; Henry 
Ford Health System, Detroit, Michigan; HealthPartners, 
Minneapolis, Minnesota; and Fallon Community Health Plan, 
Worcester, Massachusetts) were identified either through 
population-based tumor registries or health system administra-
tive data combined with medical record review. Women were 
excluded if they had been diagnosed with any other malig-
nancy (other than nonmelanoma skin cancer) either five years 
before, or 30 days following, their breast cancer diagnosis. 
Women simultaneously diagnosed with contralateral breast 
cancer were also excluded. To address possible confounding 
by receipt of chemotherapy,17 we restricted our analytic cohort 
to those women who did not receive chemotherapy.
The study protocol was approved by the institutional 
review boards at all participating organizations.
Data collection
Population cancer registries, clinical databases, and 
administrative databases were used in concert with medical 
record reviews to electronically collect demographic, tumor, 
treatment, and comorbidity data for enrolled subjects.18 
Comorbidities that were present in the year before breast 
cancer diagnosis were ascertained from medical records as 
part of a standard abstraction protocol. Date and cause of 
death were ascertained from the National Death Index.
Definition of analytic variables
For illustrative purposes, we constructed a simple index of 
comorbidity equal to the unweighted sum of health conditions 
prevalent in the year before breast cancer diagnosis. Diagnoses 
included in the index were heart failure, chronic pulmonary 
disease, connective tissue disease, cerebrovascular disease, 
dementia, diabetes, hemiplegia, hypertension, liver disease, 
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myocardial infarction, peripheral vascular disease, ulcer, 
and renal disease. These conditions, with the exception of 
hypertension, comprise a subset of  the diagnoses encompassed 
by the Charlson Comorbidity Index.2 Our subjects had 
between 0 and 7 comorbidities according to the simple index. 
The three highest categories were too sparsely populated to 
be considered independently (together they comprised ∼1% 
of the persons at risk); we therefore defined our full index 
categorization as 0, 1, 2, 3, or 4 comorbidities. Beginning 
with this full index categorization, comorbidity categories 
were sequentially collapsed by adding counts from the highest 
and next-highest levels, until comorbidity was ultimately 
categorized dichotomously (1 or 0 comorbidities). This 
process yielded four categorizations of the comorbidity 
index; the full categorization plus three orders of collapsed 
categorization (eg, Table 1).
For regression modeling and describing baseline 
cohort characteristics, age was categorized as 65–69, 
70–74, 75–79 and 80 years. For stratified analyses, age 
at breast cancer diagnosis was categorized dichotomously 
as 75 years old or 65–74 years old; this dichotomization 
provided a simple exposure categorization to use for our 
analyses of comorbidity as a confounder and modifier of the 
age/mortality association.
Tumor size was categorized as 1 cm, 1 to 2 cm, 
2 to 3 cm, and 3 cm. Lymph node status was classified 
as positive or negative based on either histologic (n = 1311; 
78%) or clinical evaluation (n = 276; 17%); 84 subjects 
(5.0%) were missing data on lymph node status. Adequate 
primary therapy was defined as having undergone either 
mastectomy or breast-conserving surgery with radiotherapy; 
other treatment regimens were classified as inadequate. 
Estrogen receptor (ER) status was classified as positive, 
negative, or indeterminate. Receipt of adjuvant tamoxifen 
therapy was classified as ever or never. To adjust for receipt 
of adjuvant tamoxifen, we created a composite variable by 
cross-tabulating ER status (positive/negative/indeterminate) 
with tamoxifen receipt (ever/never).
Mortality was defined as death from any cause occurring 
within the five years after breast cancer diagnosis.
Statistical analysis
We tabulated the frequency and risk of death from any 
cause and the total number of subjects according to age, 
Table 1 Effects of serially collapsing upper categories of a comorbidity index on inferences regarding the association between comorbidity 
burden and five-year all-cause mortality risk
Comorbidity index 
categorization
Deaths Total Risk RRunadj. (95% CI)
a RRadj. (95% CI)
a,b
Full Index
  4 29 54 0.54 4.6 (3.3, 6.4) 3.1 (2.1, 4.4)
 3 34 93 0.37 3.1 (2.2, 4.4) 2.6 (1.8, 3.7)
 2 84 292 0.29 2.5 (1.8, 3.3) 2.1 (1.5, 2.8)
 1 119 658 0.18 1.5 (1.2, 2.0) 1.3 (1.0, 1.8)
 0 67 574 0.12 1 1
1st Order
  3 63 147 0.43 3.7 (2.7, 4.9) 2.8 (2.0, 3.8)
 2 84 292 0.29 2.5 (1.8, 3.3) 2.1 (1.5, 2.8)
 1 119 658 0.18 1.5 (1.2, 2.0) 1.3 (1.0, 1.8)
 0 67 574 0.12 1 1
2nd Order
  2 147 439 0.33 2.9 (2.2, 3.7) 2.3 (1.8, 3.0)
 1 119 658 0.18 1.5 (1.2, 2.0) 1.3 (1.0, 1.8)
 0 67 574 0.12 1 1
3rd Order
  1 266 1097 0.24 2.1 (1.6, 2.7) 1.7 (1.3, 2.2)
 0 67 574 0.12 1 1
Notes: aRisk ratios and 95% confidence limits were estimated by modified Poisson regression; bAdjusted for age category, tumor size, lymph node positivity, receipt of 
adequate primary therapy, and tamoxifen receipt according to estrogen receptor status. Eighty-four subjects were excluded from adjusted models due to missing node 
positivity data.
Abbreviations: CI, confidence intervals; RR, relative risk.
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comorbidity count, and tumor and treatment characteristics 
at the time of breast cancer diagnosis (Table 2).
To assess comorbidity as an exposure variable, we 
tabulated frequencies and calculated risks of death from 
any cause within strata of all comorbidity categorizations 
(Table 1). Women with no comorbidity served as the 
reference group for all comparisons. We fit a modified 
Poisson regression model with robust standard error 
estimates to estimate mortality risk as a function of comor-
bidity level, with and without adjustment for age category, 
tumor size, lymph node status, adequacy of primary 
therapy, and adjuvant hormonal therapy (Table 1).19 The 84 
individuals with missing data for lymph node status were 
excluded from the multivariate models; results observed 
under this exclusion were nearly identical to those obtained 
after multiple imputation of the missing observations (data 
not shown).
To assess comorbidity as a candidate confounder 
or modifier, we conducted a stratified analysis of the 
association between age (75 vs 65–74 years) and all-cause 
mortality according to the comorbidity index under all 
categorizations (Table 3). Stratum-specific risk ratios 
(RR) and risk differences (RD) were calculated for the full 
and collapsed orders of the comorbidity index. For each 
comorbidity categorization, we calculated the standardized 
mortality risk ratio (SMR) across strata and divided this 
figure into the crude risk ratio (the unadjusted age/mortality 
association) to yield the relative risk due to confounding 
(RR
c
), which measures the direction and magnitude of risk 
ratio distortion due to confounding by comorbidity. The 
popular ‘change in estimate criterion’ considers a change 
of 10% as indicative of substantial confounding by a 
candidate variable, indicating that it should be retained in 
either a stratified analysis or a multivariate regression model 
of the studied association.20
Modification of the age/mortality association by 
comorbidity index was assessed on both the difference 
and ratio scales. The interaction contrast (IC; modification 
of the risk difference) was calculated as the difference 
in risk-difference values between the highest and lowest 
comorbidity strata in each categorization. Effect measure 
modification (EMM; modification of the risk ratio) was 
calculated as the ratio of the risk-ratios in the highest and 
lowest comorbidity strata in each categorization.21 A value 
of zero for the interaction contrast indicates no modifica-
tion on the difference scale, while a value of one for effect 
measure modification indicates no modification on the 
ratio scale.21
Table 2 Baseline characteristics of cohort members (N = 1,671)
Characteristic Number of 
deaths (risk)
Persons at 
risk, [n (%)]
Age at diagnosis 
(years)
 65–69 63 (0.12) 515 (31)
 70–74 89 (0.18) 493 (30)
 75–79 62 (0.21) 301 (18)
  80 119 (0.33) 362 (22)
Number of comorbid 
conditions at breast 
cancer diagnosis
 7 1 (1.0) 1 (0.1)
 6 4 (0.67) 6 (0.4)
 5 7 (0.58) 12 (0.7)
 4 17 (0.49) 35 (2.1)
 3 34 (0.37) 93 (5.6)
 2 84 (0.29) 292 (17)
 1 119 (0.18) 658 (39)
 0 67 (0.12) 574 (34)
Tumor characteristics
 Tumor size (cm)
    1 45 (0.12) 371 (22)
  1 to 2 118 (0.17) 712 (43)
  2 to 3 95 (0.25) 375 (22)
    3 75 (0.35) 213 (13)
 Node status
  Positive 74 (0.22) 329 (20)
  Negative 231 (0.18) 1,258 (75)
  (Missing) 28 (0.33) 84 (5.0)
Treatment 
characteristics
 Primary therapy
   BCS+AND+RT or 
mastectomy
209 (0.16) 1,271 (76)
  Other treatment 124 (0.31) 400 (24)
ER status/tamoxifen status
  ER+/tamoxifen- 70 (0.21) 338 (20)
  ER+/tamoxifen+ 166 (0.18) 916 (55)
  ER-/tamoxifen- 19 (0.20) 95 (5.7)
  ER-/tamoxifen+ 31 (0.31) 100 (6.0)
   ER indeterminate/
tamoxifen-
27 (0.21) 131 (7.8)
   ER indeterminate/
tamoxifen+
20 (0.22) 91 (5.4)
Abbreviations: BCS+AND, breast conserving surgery with axillary node dissection; 
ER, estrogen receptor; RT, radiotherapy.
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As an alternative to collapsing upper comorbidity 
categories to depict the association between comorbidity and 
all-cause mortality, we generated a cubic power function for 
mortality risk by maximizing the log-binomial likelihood 
of the observed data, using the entire range of comorbidity 
counts in the cohort (0 to 7 comorbidities).14 We plotted 
the observed risks at each observed comorbidity count and 
overlaid the modeled function (Figure 1).
All analyses were performed with SAS version 9.1 (SAS 
Institute, Cary, NC, USA).
Results
The BOW cohort enrolled 1,859 women. Exclusion of 
subjects who received chemotherapy yielded an analytic 
cohort of 1,671 women. The baseline characteristics of 
the analytic cohort are shown in Table 2. After five years, 
333 subjects (20%) had died and 68 subjects (4.1%) 
disenrolled from their health care system. The prevalence 
of the two lowest categories of the comorbidity index, 
0 and 1 comorbidity, were nearly equivalent (34% and 39%, 
respectively). Thereafter, comorbidity prevalence decreased 
with increasing index value; 17% of subjects had two 
comorbidities, 5.6% had three, and 3.2% had four or more.
Effect of collapsing comorbidity index  
on exposure inference
The five-year risk of death from any cause increased 
monotonically across levels of the full comorbidity index 
(Table 1), ranging from 12% for those with no comorbidities 
to 54% for those with four or more conditions. Compared 
with women with no comorbidity, those with four or more 
comorbidities had a 4.6-fold higher unadjusted risk of death 
over five years. As illustrated by the bolded risk ratios in 
Table 1, sequentially collapsing the highest comorbidity 
category into the next-highest category caused an attenuation 
of the measures of association between comorbidity and 
mortality, culminating in an unadjusted risk ratio of 2.1 
(95% confidence interval [CI]: 1.6, 2.7) when comorbidity 
was dichotomized (the 3rd order categorization). The 
percent reduction in the estimated risk ratios, compared 
with the fully categorized comorbidity index, was 20%, 
37%, and 54% for the first, second, and third collapsed 
Table 3 Effects of serially collapsing upper categories of a comorbidity index on the assessment of confounding or effect measure 
modification by comorbidity of the association between age and five-year all-cause mortality
Comorbidity index 
categorization
Age: 75 
deaths/total
Age: 65–74 
deaths/total
Risk 
ratio
Risk  
difference
SMRa RRcb ICc EMMd
Full index
  4 14/29 15/25 0.8 -0.12 1.59 1.14 -0.20 0.43
 3 14/43 20/50 0.8 -0.07
 2 54/133 30/159 2.2 0.22
 1 69/285 50/373 1.8 0.11
 0 30/173 37/401 1.9 0.08
1st Order
  3 28/72 35/75 0.8 -0.08 1.60 1.13 -0.16 0.44
 2 54/133 30/159 2.2 0.22
 1 69/285 50/373 1.8 0.11
 0 30/173 37/401 1.9 0.08
2nd Order
  2 82/205 65/234 1.4 0.12 1.63 1.11 0.04 0.77
 1 69/285 50/373 1.8 0.11
 0 30/173 37/401 1.9 0.08
3rd Order
  1 151/490 115/607 1.6 0.12 1.66 1.09 0.04 0.87
 0 30/173 37/401 1.9 0.08
Unstratified (crude) 181/663 152/1008 1.81 0.12 n/a n/a n/a n/a
Notes: aStandardized mortality risk ratio; calculated as the ratio of observed to expected deaths, based upon the risk in those aged 65–74; bRelative risk due to confounding; 
calculated as the ratio of crude risk ratio and the categorization-specific SMR values; cInteraction contrast (modification of the risk difference); difference of the risk differences 
in highest and lowest comorbidity levels; dEffect measure modification (modification of the risk ratio); ratio of the risk ratios in highest and lowest comorbidity levels.
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orders, respectively. Thus, any degree of comorbidity 
index simplification substantially altered the magnitude 
of the association observed between comorbidity and the 
outcome.
Effect of collapsing comorbidity  
on the assessment of confounding
Table 3 shows associations between older age (75 vs 
65–74 years) and five-year all-cause mortality within strata 
of different comorbidity index categorizations. The crude RR 
(unadjusted for comorbidity) for the association was 1.81. 
Standardized mortality risk ratios ranged from 1.59 for the full 
categorization to 1.66 for the dichotomized categorization; 
RR
c
 values ranged from 1.14 under the full categorization 
to 1.09 under the dichotomized categorization. Under full 
categorization, an investigator would conclude that there 
was substantial confounding by comorbidity, and would 
choose to retain it as an adjustment or stratification variable. 
This conclusion would also be reached under the first- and 
second-order collapsed categorizations. However, under the 
dichotomized categorization, an investigator might conclude 
that there was no substantial confounding by comorbidity 
(0.9 RR
c
 = 1.09 1.1), and may elect to exclude comorbidity 
from stratified tables (to avoid sparsity) or from multivariate 
regression models (to improve parsimony).
Effect of collapsing comorbidity  
on the assessment of interaction
Table 3 also shows the calculated measures of interaction 
on both the absolute (RD) and relative (RR) scales. The 
interaction contrast (modification of the RD) equaled -0.20 
under the fully categorized index, indicating that the highest 
index level and older age interacted to reduce mortality 
risk by 20 cases per 100 persons over the follow-up period, 
compared with the risk expected from the independent 
effects of age and comorbidity as well as the baseline risk. 
The interaction contrast approached the null upon sequential 
combination of upper comorbidity levels, ultimately equaling 
0.04 under the dichotomized categorization. This value 
might lead an investigator to conclude that older age and 
comorbidity had interacted to increase mortality risk by four 
cases per 100 persons over the follow-up period – a measure 
five-fold lower in magnitude and of opposite sign to that 
obtained under full categorization.
Effect measure modification (modification of the RR) 
equaled 0.43 under full categorization, indicating that the 
RR associating age and mortality in the highest comorbidity 
stratum was 57% lower than the corresponding RR in 
the no-comorbidity stratum. Thus, an investigator would 
conclude that the association between older age and mortality 
varied in magnitude (and in direction as well, in this particular 
1.0
0.8
0.6
0.4
0.2
0.0
0 1 2 3 4 5 6 7
Total comorbidities
Fi
ve
-y
ea
r m
or
ta
lit
y 
ris
k
Figure 1 Plot of five-year mortality risk as a function of comorbidity count. The diamond markers denote observed risks for each comorbidity count.  The dashed line depicts 
the risk trend described by a fitted cubic polynomial model.
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example) according to level of comorbidity index. The EMM 
measure rose in value upon sequential combination of upper 
categories of comorbidity index, ultimately equaling 0.87 
under the dichotomized categorization. This value might 
either lead to an under-appreciation of the degree of risk 
ratio modification by comorbidity status, or to an outright 
dismissal of such interaction, owing to the closeness of this 
value to unity.
A power model as an alternative  
to analyzing exposure effect
The dose-response plot in Figure 1 shows the mortality risk 
profile according to the full range of comorbidity counts 
observed in the cohort. The observed risks exhibited an 
approximately linear response pattern, affirmed by the fitted 
cubic polynomial function. This dose-response plot preserves 
the full range of exposure levels and their cognate responses, 
avoiding the pitfalls of collapsing exposure categories. 
Though our power model was univariate (comorbidity 
was the sole independent variable), such models can easily 
accommodate covariates of interest, yielding model-adjusted 
risk trends.22
Discussion
We used the sum of prevalent comorbidity diagnoses in 
the year before breast cancer diagnosis as our comorbidity 
index. While the simplicity of this index imparts limitations 
for its use as an analytic variable in an epidemiologic study, 
its role here is purely illustrative. Likewise, the association 
between older age and all-cause mortality was chosen for its 
demonstrative potential (eg, the strong associations between 
both age and death with comorbidity). We employed this 
trio of variables to demonstrate principles that may apply to 
other comorbidity scores, such as the widely used Charlson 
Comorbidity Index, and to other marginal associations of 
interest.
When comorbidity was treated as an exposure, we found 
that combining upper index categories attenuated measures of 
the association between comorbidity and all-cause mortality. 
Limiting combination to the two highest levels of the full 
index reduced the crude risk ratio by approximately one-fifth. 
Collapsing to the extreme case of dichotomization (any 
comorbidity vs none) reduced the risk ratio by more than half. 
The actual magnitude of reduction will vary depending on 
the specific index chosen, the prevalence of each index level, 
and the outcome risk for each level.7 Such reductions place 
an investigator at risk of underestimating the association 
between comorbidity and a given outcome.
Combining index categories also affected the decision 
about whether to adjust for comorbidity when using the 
popular ‘10% change in estimate’ approach for confounder 
selection. Using our fully categorized index, we saw that 
comorbidity confounded the association between older 
age and all-cause mortality, increasing the observed RR 
by 14% (RR
c
 = 1.14). Since this value is greater than the 
typical 10% cutoff for a relative change in effect estimate, 
comorbidity would be retained as a stratification variable or 
covariate in a statistical model. Our decision was different, 
however, when comorbidity was dichotomized. Under 
dichotomization, the apparent distortion due to confounding 
by comorbidity was 9%, implying that no adjustment for 
comorbidity is necessary. In our example, choosing not to 
adjust for comorbidity would yield a RR inflated 14% by 
uncontrolled confounding, compared with the RR adjusted 
for the full index. While this particular pattern is specific 
to our data, combining categories of a confounder will 
predictably dull the observed impact of the confounder on the 
studied association. That is, it will bias the relative risk due 
to confounding toward the null, compared with what would 
be observed under narrower categorization.23
Evaluation of comorbidity as a modifier of the association 
between older age and mortality showed a convergence of 
interaction measures – on both the relative and absolute 
scales – toward their null values. Under the fully categorized 
comorbidity index, modification was apparent for both 
the risk ratio and the risk difference, showing diminished 
associations when the highest comorbidity level interacted 
with older age. Both types of modification were mostly 
obscured under the second-order collapsing of comorbidity 
categories (0, 1, and 2 comorbidities), and almost 
completely obscured under the third order, dichotomization. 
The pattern we observed with effect modification should 
not be taken as illustrative of the expected bias pattern for 
all cases. Lash demonstrated that collapsing comorbidity 
generates an unpredictable and erratic pattern of effect 
modification – sometimes masking existing modification, 
and other times generating spurious modification.7 In our 
data, the pattern happened to be orderly and convergent on 
null values.
In summary, the practice of collapsing sparse upper 
categories of a comorbidity index may have important 
effects on inferences concerning comorbidity as an exposure, 
candidate confounder, or effect modifier. These limitations 
should be kept in mind when working with comorbidity 
indices. One safeguard is to collapse only adjacent upper 
categories with equal or similar outcome risks.7 When 
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feasible, alternative analyses such as power models or spline 
regression can also be adopted to preserve the rich details 
of studied associations. A simpler, though less desirable, 
solution is to restrict analyses to comorbidity categories with 
sufficient sample sizes. While this strategy limits analyses to 
persons with lower comorbidity scores, it avoids the potential 
for misinterpretation when high-comorbidity categories are 
collapsed into lower categories.
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